Dosing underway in REGENXBIO’s early-stage study of gene therapy RGX-501 in HoFH – Seeking Alpha
|
Dosing underway in REGENXBIO's early-stage study of gene therapy RGX-501 in HoFH
Seeking Alpha The first patient has been dosed in REGENXBIO's (NASDAQ:RGNX) Phase 1/2 clinical trial assessing gene therapy RGX-501 for the treatment of homozygous familial hypercholesterolemia (HoFH). Interim results are expected by year-end. The trial is an … REGENXBIO Announces Initiation of Phase I/II Clinical Trial of RGX-501 for the Treatment of Homozygous Familial … |
